Edition:
United Kingdom

Joincare Pharmaceutical Group Industry Co Ltd (600380.SS)

600380.SS on Shanghai Stock Exchange

10.98CNY
23 May 2018
Change (% chg)

¥-0.29 (-2.57%)
Prev Close
¥11.27
Open
¥11.24
Day's High
¥11.33
Day's Low
¥10.96
Volume
16,048,646
Avg. Vol
24,691,771
52-wk High
¥13.99
52-wk Low
¥8.10

Latest Key Developments (Source: Significant Developments)

Livzon Pharmaceutical Group to sell 15 pct stake in pharmaceuticals firm for 66.2 mln yuan
Tuesday, 24 Apr 2018 

April 24(Reuters) - Livzon Pharmaceutical Group Inc <000513.SZ>:Says it plans to sell 15 percent stake in a Guangdong-based pharmaceuticals company for 66.2 million yuan .Says it will hold 77.1 percent stake in the pharmaceuticals company after the transaction .  Full Article

Joincare Pharmaceutical Expects 2017 Net Profit To Rise 362.5-383.9 Percent Y/Y
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Joincare Pharmaceutical Group Industry Co Ltd <600380.SS>::SAYS IT EXPECTS 2017 NET PROFIT TO RISE 362.5-383.9 PERCENT Y/Y VERSUS 451 MILLION YUAN ($69.67 million) YEAR AGO.  Full Article

Livzon Pharmaceutical Group unit receives approval for drug clinical trial
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Livzon Pharmaceutical Group Inc <000513.SZ>:Says Zhuhai-based biotechnology unit received drug clinical trial approval for drug named Recombinant Human anti-RANKL Monoclonal Antibody Solution for Injection.  Full Article

Livzon Pharmaceutical Group unit receives approval for drug clinical trial
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Livzon Pharmaceutical Group Inc <000513.SZ>:Says its unit received drug clinical trial approval for Recombinant Humanized anti-PD-1 Monoclonal Antibody for Injection .  Full Article

Joincare Pharmaceutical Group Industry unit receives approval for drug clinical trial
Friday, 3 Nov 2017 

Nov 3(Reuters) - Joincare Pharmaceutical Group Industry Co Ltd <600380.SS>:Says co's Zhuhai-based biotechnology unit received approval for drug clinical trial, regarding recombinant humanized anti-PD-1 monoclonal antibody for injection, from China Food and Drug Administration.  Full Article

Joincare Pharmaceutical Group Industry sees FY 2017 net profit up 337.2 pct to 370.3 pct
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Joincare Pharmaceutical Group Industry Co Ltd <600380.SS>:Says it sees net profit for FY 2017 to increase 337.2 percent to 370.3 percent, or to be 1.97 billion yuan to 2.12 billion yuan.Says the net profit of FY 2016 was 451.4 million yuan.Comments that sale of unit as main reason for the forecast .  Full Article

Joincare Pharmaceutical Group's 9-month net profit up 441.9 pct y/y
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Joincare Pharmaceutical Group Industry Co Ltd <600380.SS>:Says 9-month net profit up 441.9 percent y/y.  Full Article

Joincare Pharmaceutical Group Industry units get drug clinical trial approval for Tobramycin Inhalation Solution
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Joincare Pharmaceutical Group Industry Co Ltd <600380.SS> ::Says its units and partners get drug clinical trial approval for Tobramycin Inhalation Solution.  Full Article

Joincare Pharmaceutical expects 9-month net profit to rise to 2.0-2.1 bln yuan
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Joincare Pharmaceutical Group Industry Co Ltd <600380.SS>:Says it expects 9-month net profit to rise to 2.0-2.1 billion yuan from 373.8 million yuan ($56.76 million) year ago.  Full Article

Livzon Pharmaceutical Group units receive approval for drug clinical trials
Monday, 18 Sep 2017 

Sept 18 (Reuters) - Livzon Pharmaceutical Group Inc <000513.SZ>:* Says its units received drug clinical trials approval for drug, Triptorelin Acetate Microspheres for Injection.  Full Article